Impact of 6-month earlier versus postponed initiation of rotigotine on long-term outcome: post hoc analysis of patients with early Parkinson’s disease with mild symptom severity

Bibliography

• Appel-Cresswell S, de la Fuente-Fernandez R, Galley S, et al. Imaging of compensatory mechanisms in Parkinson’s disease. Cur Opin Neurol 2010;23(4):407-12
   PubMed Web of Science ®Google Scholar
• Maetzler W, Hausdorff JM. Motor signs in the prodromal phase of Parkinson’s disease. Move Disorders 2012;27(5):627-33
   PubMed Web of Science ®Google Scholar
• Herz DM, Florin E, Christensen MS, et al. Dopamine replacement modulates oscillatory coupling between premotor and motor cortical areas in Parkinson’s disease. Cereb Cortex 2014;24(11):2873-83
   PubMed Web of Science ®Google Scholar
• Miyasaki JM, Martin W, Suchowersky O, et al. Practice parameter: initiation of treatment for Parkinson’s disease: an evidence-based review: report of the quality standards subcommittee of the american academy of neurology. Neurology 2002;58(1):11-17
   PubMed Web of Science ®Google Scholar
• Connolly BS, Lang AE. Pharmacological treatment of Parkinson disease: a review. JAMA 2014;311(16):1670-83
   PubMed Web of Science ®Google Scholar
• Schapira AH, Obeso J. Timing of treatment initiation in Parkinson’s disease: a need for reappraisal? Ann Neurol 2006;59(3):559-62
   PubMed Web of Science ®Google Scholar
• Schrag A, Dodel R, Spottke A, et al. Rate of clinical progression in Parkinson’s disease. A prospective study. Mov Disord 2007;22(7):938-45
   PubMed Web of Science ®Google Scholar
• Olanow CW, Rascol O, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease. N Eng J Med 2009;361(13):1268-78
   PubMed Web of Science ®Google Scholar
• Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson’s disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011;10(5):415-23
   PubMed Web of Science ®Google Scholar
• Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson disease. Archiv Neurol 2004;61(4):561-6
   PubMed Web of Science ®Google Scholar
• Grosset D, Taurah L, Burn DJ, et al. A multicentre longitudinal observational study of changes in self reported health status in people with Parkinson’s disease left untreated at diagnosis. J Neurol Neurosurg Psychiat 2007;78(5):465-9
   PubMed Web of Science ®Google Scholar
• AlDakheel A, Kalia LV, Lang AE. Pathogenesis-targeted, disease-modifying therapies in Parkinson disease. Neurotherapeutics 2014;11(1):6-23
   PubMed Web of Science ®Google Scholar
• Scheller D, Ullmer C, Berkels R, et al. The in vitro receptor profile of rotigotine: a new agent for the treatment of Parkinson’s disease. Naunyn Schmiedebergs Arch Pharmacol 2009;379(1):73-86
   PubMed Web of Science ®Google Scholar
• Elshoff JP, Braun M, Andreas JO, et al. Steady-state plasma concentration profile of transdermal rotigotine: an integrated analysis of three, open-label, randomized, phase I multiple dose studies. Clin Ther 2012;34(4):966-78
   PubMed Web of Science ®Google Scholar
• Watts RL, Jankovic J, Waters C, et al. Randomized, blind, controlled trial of transdermal rotigotine in early Parkinson disease. Neurology 2007;68(4):272-6
   PubMed Web of Science ®Google Scholar
• Jankovic J, Watts RL, Martin W, et al. Transdermal rotigotine: double-blind, placebo-controlled trial in Parkinson disease. Arch Neurol 2007;64(5):676-82
   PubMed Web of Science ®Google Scholar
• Giladi N, Boroojerdi B, Korczyn AD, et al. Rotigotine transdermal patch in early Parkinson’s disease: a randomized, double-blind, controlled study versus placebo and ropinirole. Mov Disord 2007;22(16):2398-404
   PubMed Web of Science ®Google Scholar
• Elmer LW, Surmann E, Boroojerdi B, et al. Long-term safety and tolerability of rotigotine transdermal system in patients with early-stage idiopathic Parkinson’s disease: a prospective, open-label extension study. Parkinsonism Relat Disord 2012;18(5):488-93
   PubMed Web of Science ®Google Scholar
• Giladi N, Boroojerdi B, Surmann E. The safety and tolerability of rotigotine transdermal system over a 6-year period in patients with early-stage Parkinson’s disease. J Neural Transm 2013;120(9):1321-9
   PubMed Web of Science ®Google Scholar
• Giladi N, Ghys L, Surmann E, et al. Effects of long-term treatment with rotigotine transdermal system on dyskinesia in patients with early-stage Parkinson’s disease. Parkinsonism Relat Disord 2014;20(12):1345-51
   PubMed Web of Science ®Google Scholar
• Oster S, Radad K, Scheller D, et al. Rotigotine protects against glutamate toxicity in primary dopaminergic cell culture. Eur J Pharmacol 2014;724:31-42
   PubMed Web of Science ®Google Scholar
• Radad K, Scheller D, Rausch WD, et al. Neuroprotective effect of rotigotine against complex I inhibitors, MPP(+) and rotenone, in primary mesencephalic cell culture. Folia Neuropathol 2014;52(2):179-86
   PubMed Web of Science ®Google Scholar
• Scheller D, Stichel-Gunkel C, Lubbert H, et al. Neuroprotective effects of rotigotine in the acute MPTP-lesioned mouse model of Parkinson’s disease. Neurosci Lett 2008;432(1):30-4
   PubMed Web of Science ®Google Scholar
• Mestre TA, Shah P, Marras C, et al. Another face of placebo: the lessebo effect in Parkinson disease: meta-analyses. Neurology 2014;82(16):1402-9
   PubMed Web of Science ®Google Scholar